The t (15; 17)(q24; q21), generating a PML-RARA fusion gene, is the hallmark of acute
promyelocytic leukemia (APL). At present, eight other genes fusing with RARA have been …

The p53 tumor suppressor protein, that has a fundamental role in growth control and
neoplasia, has been one of the most extensively studied proteins in recent years. The first …

Recent clinical studies in China showed that As2O3 is an effective and relatively safe drug in
the treatment of acute promyelocytic leukemia (APL). We found previously that As2O3 can …

Many transcription factors function by repressing gene transcription. For a variety of these
transcription factors the ability to physically recruit auxiliary proteins, denoted corepressors …

Arsenic compounds, including arsenic trioxide (As2O3) and arsenic sulfide (As4S4), have
recently been shown to be effective in the treatment of acute promyelocytic leukemia (APL) …

The c-Myb and v-Myb proteins are transcription factors that regulate cell proliferation and
differentiation. Both Myb proteins have been shown to interact with a number of cellular …

Acute promyelocytic leukemia (APL) is a rare disease accounting for only 5%–10% of
pediatric acute myeloid leukemia (AML) and fewer than 1000 cases occur annually in the …

Retinoic acids (RA) play a key role in myeloid differentiation through their agonistic nuclear
receptors (RARα/RXR) to modulate the expression of target genes. In acute promyelocytic …

Acute promyelocytic leukemia (APL) accounts for about 10% of all acute myeloid leukemias
and is characterized by the chromosomal translocation t (15; 17), which fuses the retinoic …

Signal transducer and activator of transcription (STAT) 5b-retinoic acid receptor (RAR) α is
the fifth fusion protein identified in acute promyelocytic leukemia (APL). Initially described in …